WO2002012292A3 - Method of polypeptide renaturation - Google Patents

Method of polypeptide renaturation Download PDF

Info

Publication number
WO2002012292A3
WO2002012292A3 PCT/EP2001/009023 EP0109023W WO0212292A3 WO 2002012292 A3 WO2002012292 A3 WO 2002012292A3 EP 0109023 W EP0109023 W EP 0109023W WO 0212292 A3 WO0212292 A3 WO 0212292A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
bacterium
yeast
renaturation
polypeptide renaturation
Prior art date
Application number
PCT/EP2001/009023
Other languages
French (fr)
Other versions
WO2002012292A2 (en
Inventor
Chetan Chitnis
Kailash Pandey
Sanjay Singh
Syed Shams Yazdani
Priyabrata Pattnaik
Original Assignee
Icgeb
Chetan Chitnis
Kailash Pandey
Sanjay Singh
Syed Shams Yazdani
Priyabrata Pattnaik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icgeb, Chetan Chitnis, Kailash Pandey, Sanjay Singh, Syed Shams Yazdani, Priyabrata Pattnaik filed Critical Icgeb
Priority to AU2001295450A priority Critical patent/AU2001295450A1/en
Publication of WO2002012292A2 publication Critical patent/WO2002012292A2/en
Publication of WO2002012292A3 publication Critical patent/WO2002012292A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a method for producing a polypeptide comprising a Duffy binding like (DBL) domain, wherein the method comprises: (i) expressing the polypeptide in a bacterium or as a non-secreted polypeptide in yeast; (ii) extracting the expressed polypeptide from the bacterium or yeast and denaturing the polypeptide; (iii) refolding the extracted polypeptide in the presence of arginine and urea; and optionally (iv) recovering the refolded polypeptide.
PCT/EP2001/009023 2000-08-07 2001-08-03 Method of polypeptide renaturation WO2002012292A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001295450A AU2001295450A1 (en) 2000-08-07 2001-08-03 Method of polypeptide renaturation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0019375.5A GB0019375D0 (en) 2000-08-07 2000-08-07 Method of polypeptide renaturation
GB0019375.5 2000-08-07

Publications (2)

Publication Number Publication Date
WO2002012292A2 WO2002012292A2 (en) 2002-02-14
WO2002012292A3 true WO2002012292A3 (en) 2002-05-16

Family

ID=9897148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009023 WO2002012292A2 (en) 2000-08-07 2001-08-03 Method of polypeptide renaturation

Country Status (3)

Country Link
AU (1) AU2001295450A1 (en)
GB (1) GB0019375D0 (en)
WO (1) WO2002012292A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703386D0 (en) * 1997-09-19 1997-09-19 Karolinska Innovations Ab Malaria polypeptides
DE102004041639A1 (en) * 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Method for obtaining biologically active human G-CSF from inclusion bodies
CN100457780C (en) * 2005-06-29 2009-02-04 中国人民解放军第二军医大学 Recombinant Plasmodium falciparum 175kD erythrocyte conjugated antigen functional region protein and its prepn and use
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
PL2137210T3 (en) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Novel method and compositions
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2440574B1 (en) * 2009-06-09 2021-05-26 Bharat Biotech International Limited Stable immunogenic protein having multiple cysteines molecules process therefor and composition thereof
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013108272A2 (en) * 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
MX2018004802A (en) 2015-10-19 2018-09-06 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same.
BR112019011286A2 (en) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa methods for producing a liposome composition, for preparing a vaccine composition and for preparing a vaccine kit.

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUTTA SHEETIJ ET AL: "Expression, purification and characterization of a functional region of the Plasmodium vivax Duffy binding protein.", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 109, no. 2, July 2000 (2000-07-01), pages 179 - 184, XP002192112, ISSN: 0166-6851 *
MICHON PASCAL ET AL: "Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.", INFECTION AND IMMUNITY, vol. 68, no. 6, June 2000 (2000-06-01), pages 3164 - 3171, XP002192113, ISSN: 0019-9567 *
MISAWA SATORU ET AL: "Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies.", BIOPOLYMERS., vol. 51, no. 4, 1999, pages 297 - 307, XP002192115, ISSN: 0006-3525 *
SINGH SANJAY ET AL: "Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 17111 - 17116, XP002192111, ISSN: 0021-9258 *
SMITH JOSEPH D ET AL: "Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: A parasite adhesion trait implicated in cerebral malaria.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 4, 15 February 2000 (2000-02-15), Feb. 15, 2000, pages 1766 - 1771, XP002192114, ISSN: 0027-8424 *
SWAMINATHAN S ET AL: "AFFINITY PURIFICATION OF RECOMBINANT INTERFERON-ALPHA ON A MIMETIC LIGAND ADSORBENT", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 15, no. 2, March 1999 (1999-03-01), pages 236 - 242, XP000927996, ISSN: 1046-5928 *

Also Published As

Publication number Publication date
AU2001295450A1 (en) 2002-02-18
WO2002012292A2 (en) 2002-02-14
GB0019375D0 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
WO2002012292A3 (en) Method of polypeptide renaturation
WO2008008975A3 (en) Refolding of recombinant proteins
MXPA03010433A (en) Methods for the recombinant production of antifusogenic peptides.
WO2004026857A3 (en) Methods of purifying cannabinoids from plant material
WO2000075336A3 (en) Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines
WO2002006510A3 (en) Photoselection of nucleic acid ligands
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2005061716A3 (en) Expression vector used for antibiotic-free expression
WO2005000888A3 (en) NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
HK1076633A1 (en) Production process of recombinant placental growth factor
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2007130154A8 (en) Recombinant production of heparin binding proteins
WO2008033555A3 (en) High-pressure refolding of difficult-to-fold proteins
WO2004020639A3 (en) Production of multimeric fusion proteins using a c4bp scaffold
WO2002016617A3 (en) Myrosinase from brevicoryne brassicae
WO2005058930A3 (en) Methods for production of recombinant vascular endothelial cell growth inhibitor
EP1161862A3 (en) See-through medaka
WO2002012468A3 (en) 2,5-dkg permeases
WO2004087912A8 (en) Inhibitor proteins of a protease and use thereof
WO2005017237A3 (en) Apparatus and method for the selective assembly of protein
WO2004016550A3 (en) Method for opening carbon nanotubes at the ends thereof and implementation
WO2001014407A3 (en) Refolding of membrane proteins, using two different detergents
NO20063280L (en) Method of purifying bacterially expressed proteins
AU8769501A (en) Method for purifying recombinant proteins expressed as insoluble aggregates
WO1999064451A3 (en) Plant protein with repeated wd40 motifs, nucleic acid coding for said protein, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP